Does TRIMIPRAMINE Cause Bladder transitional cell carcinoma? 7 Reports in FDA Database
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Bladder transitional cell carcinoma have been filed in association with TRIMIPRAMINE (Trimipramine Maleate). This represents 1.0% of all adverse event reports for TRIMIPRAMINE.
7
Reports of Bladder transitional cell carcinoma with TRIMIPRAMINE
1.0%
of all TRIMIPRAMINE reports
0
Deaths
7
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From TRIMIPRAMINE?
Of the 7 reports, 7 (100.0%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TRIMIPRAMINE. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does TRIMIPRAMINE Cause?
Toxicity to various agents (85)
Off label use (66)
Somnolence (64)
Nausea (60)
Coma (59)
Dizziness (58)
Drug abuse (57)
Abdominal pain upper (46)
Headache (46)
Vomiting (45)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which TRIMIPRAMINE Alternatives Have Lower Bladder transitional cell carcinoma Risk?
TRIMIPRAMINE vs TRIPROLIDINE
TRIMIPRAMINE vs TRIPTORELIN
TRIMIPRAMINE vs TRISODIUM
TRIMIPRAMINE vs TROFINETIDE
TRIMIPRAMINE vs TROFOSFAMIDE